News
INMD
17.36
+0.70%
0.12
Analysts Conflicted on These Healthcare Names: InMode (INMD) and Pfizer (PFE)
TipRanks · 12h ago
INMD Stock Earnings: InMode Misses EPS, Misses Revenue for Q1 2024
InMode reported earnings per share of 32 cents for the first quarter of 2024. The company reported revenue of $80.28 million. InMode's revenue was 13.69% lower than the analyst estimate for the same period. In mode is a software company that designs and sells mobile devices.
Investorplace · 16h ago
INMD Earnings: Buybacks Aren’t Enough to Overcome Earnings Miss
TipRanks · 16h ago
InMode Announces Q1 Results and Share Buyback
TipRanks · 20h ago
InMode Q1 Adj $0.32 Misses $0.44 Estimate, Sales $80.28M Miss $93.02M Estimate
In Mode reported quarterly earnings of $0.32 per share. The company reported quarterly sales of $80.28 million. In Mode missed the analyst consensus estimate of $93.02 million by 13.69%. The company's quarterly sales are down 38.46 percent from the same period last year.
Benzinga · 21h ago
InMode: Q1 Earnings Snapshot
InMode Ltd. Reports earnings of $23.7 million in its first quarter. The maker of cosmetic surgery devices posted revenue of $80.3 million in the period. InMode expects full-year earnings in the range of $2.01 to $3.05.
Barchart · 1d ago
Notable earnings before Thursday's open
Major earnings expected before the bell on Thursday include: ConocoPhillips (COP) and Shell (SHEL) Other earnings slated for release before Thursday's open include: Iron Mountain, Moderna, Organon and Shell. Notable earnings before the close of trading on Wednesday include: Exxon Mobil (XOM) and Chevron.
Seeking Alpha · 1d ago
TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 1d ago
Weekly Report: what happened at INMD last week (0422-0426)?
Weekly Report · 3d ago
InMode: More Headwinds Than Expected, Wait For A Floor To Materialize (Rating Downgrade)
InMode Ltd. (INMD) has declined by -21.6% over the past three months. The stock is underperforming the wider market at +4.7%. The market remains pessimistic about INMD's prospects. The management's lowered FY2024 revenue guidance is attributed to the "macro headwinds" We are prudently downgrading INMD to a Hold for now.
Seeking Alpha · 5d ago
Weekly Report: what happened at INMD last week (0415-0419)?
Weekly Report · 04/22 09:30
Commit To Purchase InMode At $10, Earn 11% Using Options
NASDAQ · 04/19 15:34
InMode Defends Its Feminine Rejuvenation Patent Against BTL Industries' Review Request
InMode Ltd. Responds to petition to the U.S. Patent & Trademark Office filed by BTL Industries, Inc. Six months ago, InMode sued BTL for alleged infringement of its patent. The litigation is ongoing. In mode is a leading provider of innovative medical technologies.
Benzinga · 04/15 11:08
INMODE RESPONDS TO BTL PETITION FOR INTER PARTES REVIEW OF PATENT INMODE IS ASSERTING AGAINST BTL
Reuters · 04/15 11:02
Weekly Report: what happened at INMD last week (0408-0412)?
Weekly Report · 04/15 09:27
InMode Is Maintained at Overweight by Barclays
Dow Jones · 04/12 14:09
InMode Price Target Cut to $33.00/Share From $34.00 by Barclays
Dow Jones · 04/12 14:09
Barclays Maintains Overweight on InMode, Lowers Price Target to $33
Benzinga · 04/12 13:59
3 Best Stocks to Buy Now, 4/12/2024, According to Top Analysts 
According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and has a significant upside as well. Mondelez International, Intapp and In Mode are among the top picks, according to analysts.
TipRanks · 04/12 09:43
Barclays Keeps Their Buy Rating on InMode (INMD)
TipRanks · 04/12 07:35
More
Webull provides a variety of real-time INMD stock news. You can receive the latest news about Inmode Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About INMD
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.